Kolexia
Sablin Marie-Paule Oncologie médicale
Sablin Marie-Paule
Oncologie médicale
Clcc Institut Curie
Paris, France
153 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Carcinomes Tumeurs du sein triple-négatives Récidive tumorale locale Carcinome épidermoïde Tumeurs du poumon Tumeurs de la tête et du cou Carcinome épidermoïde de la tête et du cou

Collaborateurs

Voir plus
Le Tourneau Christophe
Le Tourneau Christophe
Clcc Institut Curie, Paris, France
Loirat Delphine
Loirat Delphine
Clcc Institut Curie, Paris, France
Bieche Ivan
Bieche Ivan
Institut Curie, Saint-Cloud, France
Goncalves Anthony
Goncalves Anthony
Centre Paoli-Calmettes, Marseille, France

Industries

Voir plus
A+A
58 collaboration(s)
Dernière en 2021
B3TSI
31 collaboration(s)
Dernière en 2021
Ipsos Mori UK Limited
26 collaboration(s)
Dernière en 2020
P\S\L Group Services
24 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors: A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
Essai Clinique (BMS)   06 mars 2024
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis.
Oncogene   27 février 2024
Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine.
BMC biology   20 février 2024
SHIVA02 - Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control
Essai Clinique (Institut Curie)   15 février 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules: A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies
Essai Clinique (AstraZeneca)   19 janvier 2024
SAFIR02_Breast: PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Essai Clinique (Unicancer)   09 janvier 2024
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results.
Clinical cancer research : an official journal of the American Association for Cancer Research   07 décembre 2023
MegaMOST - A Multicenter, Open-label, Biology Driven, Phase II Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations /Characteristics in Advanced / Metastatic Tumors.
Essai Clinique (Centre Léon-Bérard)   16 novembre 2023
138P Precision medicine phase II study evaluating the efficacy of olaparib in patients with progressive solid cancers and carriers of homologous recombination repair genes alterations
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023